دورية أكاديمية
أعرض في EDS

Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials

التفاصيل البيبلوغرافية
العنوان: Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials
المؤلفون: Wang H, Wang HF, Yu ZC, Liu HH
المصدر: OncoTargets and Therapy, Vol Volume 11, Pp 5195-5201 (2018)
بيانات النشر: Dove Medical Press, 2018.
سنة النشر: 2018
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: sorafenib, tyrosine kinase inhibitors, selective internal radiotherapy, hepatocellular carcinoma, meta-analysis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Hui Wang, Hefang Wang, Zhichong Yu, Honghao Liu Department of Radiation Oncology, Yancheng First People’s Hospital, Yancheng, Jiangsu 224005, China Introduction: This meta-analysis was conducted to evaluate efficacy and safety in patients treated with sorafenib vs other tyrosine-kinase inhibitors (TKIs) or selective internal radiotherapy (SIRT) for advanced hepatocellular carcinoma (HCC).Methods: Electronic databases were systematically reviewed for randomized Phase III trials comparing sorafenib with other TKIs or SIRT in advanced HCC. Sorafenib was defined as the control arm. Other TKIs or SIRT was defined as the experimental arm. Overall survival (OS), time to progression (TTP), objective response rate (ORR), disease-control rate (DCR), and adverse events (AEs) were reviewed. Four trials in the other-TKI group (n=4,218) and two in the SIRT group (n=819) were eligible.Results: Compared with sorafenib, other TKIs showed similar benefit on OS (HR 1.08, 95% CI 0.93–1.24; P=0.31) and TTP (HR 0.86, 95% CI 0.66–1.12; P=0.26) for advanced HCC. A significant increase in ORR (RR 1.67, 95% CI 1.15–2.43; P=0.008) was found with other TKIs, but no increase in DCR (RR 1.11, 95% CI 0.98–1.26; P=0.11) was observed. Other TKIs were associated with more frequent grade 3/4 AEs than sorafenib, including hypertension (P
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1178-6930
63013568
Relation: https://www.dovepress.com/alternative-treatment-strategies-to-sorafenib-in-patients-with-advance-peer-reviewed-article-OTT; https://doaj.org/toc/1178-6930
URL الوصول: https://doaj.org/article/7a8d80636d5f4b39b15e63013568ae33
رقم الأكسشن: edsdoj.7a8d80636d5f4b39b15e63013568ae33
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:11786930
63013568